Home

Myriad Genetics, Inc. - Common Stock (MYGN)

4.4550
+0.2650 (6.32%)
NASDAQ · Last Trade: Jun 2nd, 3:47 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close4.190
Open4.240
Bid4.450
Ask4.460
Day's Range4.170 - 4.520
52 Week Range3.812 - 29.30
Volume2,125,315
Market Cap410.75M
PE Ratio (TTM)-3.942
EPS (TTM)-1.1
Dividend & YieldN/A (N/A)
1 Month Average Volume3,395,195

Chart

About Myriad Genetics, Inc. - Common Stock (MYGN)

Myriad Genetics is a molecular diagnostics company that focuses on developing and delivering innovative genetic testing and personalized medicine solutions. The company aims to empower healthcare providers and patients with valuable insights into genetic predispositions for various health conditions. Its comprehensive portfolio includes tests for hereditary cancer risk, pharmacogenomics, and other complex diseases, enabling informed medical decision-making and tailored treatment plans. By leveraging advanced technologies in genetics and genomics, Myriad Genetics strives to enhance patient care and improve clinical outcomes. Read More

News & Press Releases

Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types
MONSTAR-SCREEN-3 study showed 100% detection of circulating tumor DNA (ctDNA) at baseline timepoint, and 60% of patients testing positive one month after surgery had tumor fractions only detectable via ultra-sensitive MRD
By Myriad Genetics, Inc. · Via GlobeNewswire · June 2, 2025
3 Cash-Burning Stocks Facing Headwinds
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.
Via StockStory · May 30, 2025
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators
By Myriad Genetics, Inc. · Via GlobeNewswire · May 27, 2025
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Myriad Genetics (NASDAQ:MYGN) and its peers.
Via StockStory · May 26, 2025
3 Small-Cap Stocks with Questionable Fundamentals
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
Via StockStory · May 22, 2025
This UnitedHealth Group Analyst Turns Bearish; Here Are Top 3 Downgrades For Wednesdaybenzinga.com
Via Benzinga · May 21, 2025
MYGN Q1 Earnings Call: Guidance Cut Amid GeneSight Challenges and Slow Hereditary Cancer Ramp
Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 3.1% year on year to $195.9 million. The company’s full-year revenue guidance of $815 million at the midpoint came in 3.7% below analysts’ estimates. Its non-GAAP loss of $0.03 per share was $0.02 above analysts’ consensus estimates.
Via StockStory · May 19, 2025
CI&T, Novavax, Paramount Group And Other Big Stocks Moving Higher On Mondaybenzinga.com
Via Benzinga · May 19, 2025
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
Correction: Time of BofA Conference
By Myriad Genetics, Inc. · Via GlobeNewswire · May 14, 2025
3 of Wall Street’s Favorite Stocks in Dangerous Territory
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Via StockStory · May 12, 2025
Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) investors concerning the Company’s possible violations of the federal securities laws.
Myriad Genetics, Inc. (MYGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Law Offices of Howard G. Smith announces an investigation on behalf of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) investors concerning the Company’s possible violations of federal securities laws.
Myriad Genetics Shares Tank 41% On Analyst Downgrades, Weaker Guidance: Yet Retail Investors Remain Bullishstocktwits.com
Analysts, including those from Wells Fargo, UBS, Raymond James, and Craig-Hallum, slashed their price targets and expressed concerns over the company's growth and execution challenges.
Via Stocktwits · May 7, 2025
Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz announces an investigation of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) on behalf of investors concerning the Company’s possible violations of federal securities laws.
What Analysts Are Saying About Myriad Genetics Stockbenzinga.com
Via Benzinga · May 7, 2025
Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology
Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk
By Myriad Genetics, Inc. · Via GlobeNewswire · May 7, 2025
Why Myriad Genetics (MYGN) Stock Is Down Today
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 36% in the afternoon session after the company reported mixed first quarter 2025 results: it lowered its full-year revenue, EPS, and EBITDA guidance due to weaker trends in its pharmacogenomics and hereditary cancer testing (women's health) businesses. On the other hand, MYGN significantly beat analysts' EPS and EBITDA expectations. Overall, this was a softer quarter.
Via StockStory · May 7, 2025
Top movers in Wednesday's sessionchartmill.com
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · May 7, 2025
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga.com
Via Benzinga · May 7, 2025
Crude Oil Falls 1%; Uber Sales Miss Estimatesmarkets/com
Via Benzinga · May 7, 2025
Wednesday's session: top gainers and loserschartmill.com
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · May 7, 2025
Let's uncover which stocks are experiencing notable gaps during today's session.chartmill.com
In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.
Via Chartmill · May 7, 2025
These stocks that are showing activity before the opening bell on Wednesday.chartmill.com
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.
Via Chartmill · May 7, 2025
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · May 7, 2025
Myriad Genetics (NASDAQ:MYGN) Misses Q1 Sales Targets, Stock Drops 14.5%
Genetic testing company Myriad Genetics (NASDAQ:MYGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.1% year on year to $195.9 million. The company’s full-year revenue guidance of $815 million at the midpoint came in 3.7% below analysts’ estimates. Its non-GAAP loss of $0.03 per share was $0.02 above analysts’ consensus estimates.
Via StockStory · May 6, 2025